A patient under the care of Dr. Enrique Lafont, St. Gallen, Switzerland, presented with Rutherford classification 5, with non-healing ulcers on the right foot. On angiographic assessment, an occlusion of the popliteal at the P1 segment was observed with heavy disease of P2 and P3 segment and single-vessel runoff to the foot.
Dr. Lafont selected a 6mm IVL catheter, which was used to treat the popliteal, and following treatment, there were no angiographic signs of dissection or distal embolization. Dr. Lafont then proceeded with a 6mm DCB to complete treatment with no adjunctive stenting required.
1Tepe et al., J Am Coll Cardiol Intv 2021
2E. Armstrong, VIVA Late Breaking Clinical Trial 2022
IVL maintains control of the procedure by minimizing complications such as dissections, embolization and perforations. IVL significantly reduces the need for bailout stents, preserving future treatment options.
1Tepe et al., J Am Coll Cardiol Intv 2021
IVL has demonstrated excellent patency out to two years in a severely calcified patient population.
*Primary Patency defined as freedom from provisional stenting at index procedure, freedom from clinically-driven target lesion revascularization and freedom from restenosis determined by duplex ultrasound
1Tepe et al., J Am Coll Cardiol Intv 2021
Interested in learning more? Read the online Vascular News supplement, “Change compliance to change the game in PAD treatment” to learn how IVL is evolving calcium management in ATK lesions.
Looking for careers? Click here.
